Approximately 30% of American adults are diagnosed with hypertension; however, only ~50% achieve adequate blood pressure (BP) control with current therapeutic options. Preclinical data demonstrate that a sexual dimorphism exists for angiotensin 1-7 (Ang (1-7)), a vasodilatory peptide that has therapeutic promise in controlling BP. This study sought to determine if 1) sex and race differences in Ang (1-7) are present in normotensives adults, and 2) increases in Ang (1-7) are related to lower BP in hypertensive adults. Blood samples, BP, and flow-mediated dilation (FMD, n=29) were assessed in 45 adults (52% women, 44% African American (AA)). Systolic BP was lower (p=0.013) in women compared to men (111±4 mm Hg vs. 126±4 mm Hg) and higher (p=0.024) in AA compared to Caucasians (C; 125±4 mm Hg vs. 111±4 mm Hg). Diastolic BP was higher (p=0.021) in AA compared to C (77±3 mm Hg vs. 65±4 mm Hg). Overall, Ang (1-7) was highest in C women (44±5 pg/ml) followed by AA women (38±5 pg/ml), C men (33±4 pg/ml), and AA men (30±6 pg/ml). Only within C was a significant correlation between FMD and Ang (1-7) observed (r=0.573;p=0.041). Overall, the change in Ang (1-7) following treatment with candesartan (n=6) was positively associated with the change in FMD (r=0.485) and inversely associated with the change in systolic BP (r=-0.431). These data are the first to identify, in humans, the existence of a sexual and racial dimorphism in Ang (1-7). Our findings support the therapeutic potential of Ang (1-7) to reduce BP and improve endothelial function in hypertensive adults.